Einat Brill‐Almon

1.3k citations

27 papers · 655 indexed · h-index 11

Co-authors: David Aviezer Yoseph Shaaltiel Daniel Bartfeld Sharon Hashmueli Gad Galili Orly Dym Joel L. Sussman Ari Zimran
Topics: Lysosomal Storage Disorders Research (24 papers)Carbohydrate Chemistry and Synthesis (12 papers)Glycosylation and Glycoproteins Research (7 papers)
Cited by: Biotechnology Physiology Cell Biology
Journals: Blood PLoS ONE Molecular Therapy
Partner nations: Israel United Kingdom United States

In The Last Decade

Einat Brill‐Almon

25 papers receiving 625 citations

Peers

Countries citing papers authored by Einat Brill‐Almon

Since Specialization

Citations

This map shows the geographic impact of Einat Brill‐Almon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Einat Brill‐Almon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Einat Brill‐Almon more than expected).

Fields of papers citing papers by Einat Brill‐Almon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Einat Brill‐Almon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Einat Brill‐Almon. The network helps show where Einat Brill‐Almon may publish in the future.

Co-authorship network of co-authors of Einat Brill‐Almon

This figure shows the co-authorship network connecting the top 25 collaborators of Einat Brill‐Almon. A scholar is included among the top collaborators of Einat Brill‐Almon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Einat Brill‐Almon. Einat Brill‐Almon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study 2023 ·Orphanet Journal of Rare Diseases ·Aleš Linhart,Gabriela Dostálová,Kathy Nicholls,Michael L. West,Camilla Tøndel,Ana Jovanović,Pilar Giraldo,Bojan Vujkovac,Tarekegn Geberhiwot,Einat Brill‐Almon,Sari Alon,Raul Chertkoff,(unknown),Derralynn Hughes	24
2	FP805PROGRESSION OF NEPHROPATHY IN FABRY PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY (ERT); RELATION TO ANTI-DRUG ANTIBODY (ADA) STATUS AND PROTEINURIA 2018 ·Nephrology Dialysis Transplantation ·David G. Warnock,Sari Alon,Raul Chertkoff,Einat Brill‐Almon	1
3	Pegunigalsidase alfa, a novel PEGylated ERT for Fabry disease: Two-year safety and efficacy follow up 2018 ·Molecular Genetics and Metabolism ·Derralynn Hughes,Pilar Giraldo,Myrl Holida,Özlem Göker-Alpan,Gustavo Maegawa,Raphael Schiffmann,Sari Alon,(unknown),(unknown),Einat Brill‐Almon,Raul Chertkoff	2
4	WS01.2 Phase II clinical trial results of alidornase alfa for the treatment of cystic fibrosis 2017 ·Journal of Cystic Fibrosis ·Eitan Kerem,H. Blau,Michal Shteinberg,Ori Efrati,Alon Scope,(unknown),(unknown),(unknown),Einat Brill‐Almon,(unknown),Yoseph Shaaltiel,Lea Bentur	4
5	PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study 2017 ·Molecular Genetics and Metabolism ·David G. Warnock,Derralynn Hughes,(unknown),Pilar Giraldo,Derlis Gonzalez,Myrl Holida,Özlem Göker-Alpan,Gustavo Maegawa,Mohamed G. Atta,Kathy Nicholls,Raphael Schiffmann,Ahmad Tuffaha,(unknown),Raul Chertkoff,Sari Alon,Einat Brill‐Almon	2
6	One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy 2017 ·Molecular Genetics and Metabolism ·Derralynn Hughes,(unknown),Pilar Giraldo,Derlis Gonzalez,Myrl Holida,Özlem Göker-Alpan,Gustavo Maegawa,Mohamed G. Atta,Kathy Nicholls,Raphael Schiffmann,Ahmad Tuffaha,Laura Barisoni,Robert B. Colvin,(unknown),(unknown),(unknown),Einat Brill‐Almon,Raul Chertkoff	1
7	Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase 2016 ·American Journal of Hematology ·Gregory M. Pastores,Suma P. Shankar,Мilan Petakov,Pilar Giraldo,Hanna Rosenbaum,Dominick Amato,Jeff Szer,Raul Chertkoff,Einat Brill‐Almon,Ari Zimran	18
8	Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naïve previously treated with immiglucerase 2015 ·Molecular Genetics and Metabolism ·Ari Zimran,(unknown),Aya Abrahamov,Peter A. Cooper,(unknown),Alona Paz,Einat Brill‐Almon,Raul Chertkoff	1
9	Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R 2015 ·Toxicology and Applied Pharmacology ·Jacob Atsmon,Einat Brill‐Almon,(unknown),Raul Chertkoff,Sari Alon,(unknown),(unknown),(unknown),Daniel Bartfeld,Avidor Shulman,(unknown),Tehila Ben-Moshe,(unknown),Hermona Soreq,Yoseph Shaaltiel	16
10	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase 2014 ·Gregory M. Pastores,Мilan Petakov,Pilar Giraldo,Hanna Rosenbaum,Jeff Szer,Patrick Deegan,Dominick Amato,Eugen Mengel,Ee Shien Tan,Raul Chertkoff,Einat Brill‐Almon,Ari Zimran	1
11	A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase 2014 ·Blood Cells Molecules and Diseases ·Gregory M. Pastores,Мilan Petakov,Pilar Giraldo,Hanna Rosenbaum,Jeff Szer,Patrick Deegan,Dominick Amato,Eugen Mengel,Ee Shien Tan,Raul Chertkoff,Einat Brill‐Almon,Ari Zimran	46
12	Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease 2014 ·Blood Cells Molecules and Diseases ·Ari Zimran,(unknown),Aya Abrahamov,Deborah Elstein,Alona Paz,Einat Brill‐Almon,Raul Chertkoff	25
13	Long-term safety and efficacy data of taliglucerase alfa, a Plant cell-expressed recombinant glucocerebrosidase, in the treatment of naïve Gaucher disease patients: 36-Month Results 2013 ·Molecular Genetics and Metabolism ·Ari Zimran,Atul Mehta,Pilar Giraldo,Hanna Rosenbaum,Fiorina Giona,Dominick Amato,Мilan Petakov,(unknown),Sergio Solorio,(unknown),Deborah Elstein,Raul Chertkoff,Einat Brill‐Almon	2
14	Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease 2012 ·Blood Cells Molecules and Diseases ·Laura van Dussen,Ari Zimran,Erik M. Akkerman,Johannes M. F. G. Aerts,Мilan Petakov,Deborah Elstein,Hanna Rosenbaum,David Aviezer,Einat Brill‐Almon,Raul Chertkoff,Mario Maas,Carla E. M. Hollak	31
15	Long Term Safety and Efficacy Data of Taliglucerase Alfa, a Plant Cell Expressed Recombinant Glucocerebrosidase, in Treatment Of Naïve Gaucher Disease Patients 2012 ·Molecular Genetics and Metabolism ·Ari Zimran,René Heitner,Atul Mehta,Pilar Giraldo,Hanna Rosenbaum,(unknown),Dominick Amato,Мilan Petakov,(unknown),(unknown),(unknown),Deborah Elstein,Einat Brill‐Almon	3
16	Long Term Bone Marrow Responses, as Measured by Quantitative Chemical Shift Imaging (QCSI) MRI, Following Treatment With Taliglucerase Alfa in Patients with Type 1 Gaucher Disease 2012 ·Molecular Genetics and Metabolism ·Laura van Dussen,Carla E. M. Hollak,Ari Zimran,(unknown),Hanna Rosenbaum,David Aviezer,Einat Brill‐Almon,Raul Chertkoff,Mario Maas	2
17	Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model 2010 ·Blood Cells Molecules and Diseases ·Luc Bracoud,(unknown),Einat Brill‐Almon,Raul Chertkoff	15
18	A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation 2009 ·PLoS ONE ·David Aviezer,Einat Brill‐Almon,Yoseph Shaaltiel,Sharon Hashmueli,Daniel Bartfeld,(unknown),(unknown),Arnold I. Freeman,Ari Zimran,(unknown)	128
19	Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system 2007 ·Plant Biotechnology Journal ·Yoseph Shaaltiel,Daniel Bartfeld,Sharon Hashmueli,Gideon Baum,Einat Brill‐Almon,Gad Galili,Orly Dym,Swetlana Boldin‐Adamsky,Israel Silman,Joel L. Sussman,Anthony H. Futerman,David Aviezer	277
20	Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins 2005 ·Molecular Therapy ·Einat Brill‐Almon,(unknown),Daniel Afik,Joel Kaye,(unknown),(unknown),(unknown),(unknown),(unknown),Amos Panet,Noam Shani	28

About Einat Brill‐Almon

Einat Brill‐Almon is a scholar working on Physiology, Biotechnology and Organic Chemistry, having authored 27 papers that have together received 655 indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (24 papers), Carbohydrate Chemistry and Synthesis (12 papers) and Glycosylation and Glycoproteins Research (7 papers). The work is most often cited by research in Biotechnology (307 citations), Physiology (289 citations) and Cell Biology (114 citations). Einat Brill‐Almon has collaborated with scholars based in Israel, United Kingdom and United States. Frequent co-authors include David Aviezer, Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli, Gad Galili, Orly Dym, Joel L. Sussman, Ari Zimran, Israel Silman and Swetlana Boldin‐Adamsky. Their work appears in journals such as Blood, PLoS ONE and Molecular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact